Johnson & Johnson (UKEX:JNJ)
â‚´ 5947 0 (0%) Market Cap: 14.82 Til Enterprise Value: 15.47 Til PE Ratio: 24.01 PB Ratio: 4.98 GF Score: 84/100

Johnson & Johnson at Leerink Partners Global Healthcare Conference Transcript

Feb 28, 2019 / 04:00PM GMT
Danielle Joy Antalffy
SVB Leerink LLC, Research Division - MD of Medical Supplies & Devices and Senior Analyst

Good morning. Oh, can you hear me? Okay. Perfect. Good morning, everyone. Welcome to the SVB Leerink Healthcare Conference. My name is Danielle Antalffy. I am one of the medtech analysts here at SVB Leerink. And we are very lucky to have with us from Johnson & Johnson, Ashley McEvoy. So let me make sure I get your title correct, EVP and Worldwide Chairman of Medical Devices. And also from Investor Relations, we have Chris DelOrefice and also Matthew Stuckley. He will start us off with some of the disclosures.

Matt Stuckley
Johnson & Johnson - VP of IR

Thanks, Danielle. Good morning, everyone. Please be aware that some statements made today may be considered forward-looking or utilize non-GAAP measures. Please refer to our SEC filings, in particular, our 10-K, which discuss the risks and uncertainties around forward-looking statements as well as our website at investor.jnj.com for reconciliations to comparable GAAP measures. Finally, any

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot